INDIVIDUAL ARTICLE: Clinical and Real-World Implications of IL-17 Receptor Blockade in Plaque Psoriasis and Psoriatic Arthritis With Brodalumab [0.03%]
依鲁利珠单抗（brodalumab）对斑块状银屑病和银屑病关节炎患者血清IL-17受体阻断的临床及真实世界意义
Naiem T Issa,James Krueger,Mark Lebwohl et al.
Naiem T Issa et al.
Brodalumab is a fully human monoclonal antibody targeting interleukin-17 receptor A (IL-17RA), providing a mechanistically distinct approach to inhibiting IL-17–mediated inflammation in plaque psoriasis and psoriatic arthritis (approv...
Malassezia Folliculitis Presentation, Diagnosis, and Treatment: A Review of "Fungal Acne" [0.03%]
马拉瑟菌毛囊炎的临床表现、诊断和治疗：“真菌性痤疮”文献综述
Zoe D Draelos,John S Barbieri,Emil A Tanghetti et al.
Zoe D Draelos et al.
Background: Malassezia folliculitis (MF), commonly referred to as "fungal acne" is a dermatological condition caused by colonization of the commensal fungus Malassezia, which turns pathogenic under certain conditions. MF ...
Time is Tissue: A Representative Case Report Highlighting the Importance of Early Clinical Diagnosis of Necrotizing Fasciitis [0.03%]
时间就是组织：早期临床诊断坏死性筋膜炎重要性的病例报告
Hayden Y K Fung,Vicki C Tse,Adam Friedman
Hayden Y K Fung
Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel [0.03%]
Cosibelimab治疗晚期皮肤鳞状细胞癌的疗效和安全性专家共识意见书
Brooke Bartley,Angela Rosenberg,Lauren DeBusk et al.
Brooke Bartley et al.
Background: Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are not candidates for surgery or radiation. In...
Zoe Draelos,Joshua Zeichner,Dara Miller et al.
Zoe Draelos et al.
Modern skin cleansers have evolved from basic soaps to advanced cleansing formulations that also provide moisturization and skin barrier support. Surfactants work by emulsifying oils and reducing surface tension, but they may disrupt essent...
Safety and Efficacy of Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for Facial Cutaneous Squamous Cell Carcinoma in situ [0.03%]
氨基乙醛酸20％ topical溶液激活的蓝色光用于治疗原位面部鳞状细胞皮肤癌的安全性和有效性
Mark S Nestor,Aysham Chaudry,Robert J Vanaria et al.
Mark S Nestor et al.
Background: Squamous cell carcinoma in situ (isSCC) is an early-stage cutaneous malignancy that requires effective treatment to prevent progression to invasive SCC. Aminolevulinic acid photodynamic therapy (ALA-PDT) is a ...
Efficacy and Safety of Topical Metformin vs Kligman Formula in the Treatment of Melasma: A Split-Face Study [0.03%]
甲硝唑与克利格曼配方治疗黄褐斑的疗效及安全性：分裂脸研究
Eman Ayesha,Sumera Hanif,Sandy Agaiby et al.
Eman Ayesha et al.
Background: Melasma is an acquired pigmentary disorder characterized by symmetrical hyperpigmented macules and patches on sun-exposed areas, primarily the face. Kligman's formula, or "triple combination cream," is widely ...
Comparative Study
Journal of drugs in dermatology : JDD. 2026 May 1;25(5):435-439. DOI:10.36849/JDD.9193 2026
Longer Pembrolizumab Therapy Reduces Mortality in Stage III and IV Melanoma: A TriNetX Study [0.03%]
帕博利珠单抗延长治疗可降低III期和IV期黑色素瘤患者的死亡率：一项TriNetX研究结果
Mackenzie Gipple,Neal Gupta,Maile Ray et al.
Mackenzie Gipple et al.
Background: Melanoma is the leading cause of skin-cancer-related mortality worldwide. Anti-programmed cell death protein-1 therapies, including pembrolizumab, play a critical role in treating advanced melanoma. However, t...
Clinical Methodology to Evaluate the Efficacy of a Topical Cosmetic Eye Formulation on the Appearance of Dynamic Periorbital Lines [0.03%]
评估外用化妆品眼霜改善动态眉间纹功效的临床试验方法
Elizabeth Bruning,Martin Keh,Uma Santhanam et al.
Elizabeth Bruning et al.
Background: Dynamic lines in the periorbital region are the first signs of aging. Dynamic lines show only when emoting, possibly becoming static lines present with worsening with age. ...
Sam Fathizadeh,Melanie D Palm,Deirdre Hooper
Sam Fathizadeh
Background: Rapid and intentional weight loss can result from bariatric surgery, pharmacologic agents such as glucagon-like peptide-1 receptor agonists, and intensive lifestyle changes. Although effective in lowering body...